All News

Each year, the Office of the Inspector General at the Department of Health and Human Services publishes a summary of its activities and a work plan for the coming year. What follows is a summary of new topics in the FY2017 work plan that may be of interest to urologists.

Adherence to guidelines for the use of combination radiation therapy and androgen deprivation therapy in the United States for the treatment of high-risk or locally advanced prostate cancer has decreased over time, according to data presented by Paolo Dell’Oglio, MD.

Despite the excruciating nature of kidney stones, many people can't manage to lower their risk by simply drinking more liquid. Now, a new study finds that one potential tool-a water bottle with a built-in consumption sensor and smartphone link-accurately tracks how much people drink.

The Affordable Care Act's controversial contraceptive coverage mandate requires most private health plans to provide cost-free coverage of female contraception. Reproductive health advocates in many states are pressing for new laws that include vasectomy in those covered services.

“Be honest and forthright but try to do it as compassionately as possible,” one urologist advises.

A comparison of dusting versus basketing, the question of whether shock wave lithotripsy should be retired, and an expert interview on difficult stones were among the most-read Urology Times articles on stone disease in 2016.

“It is clear that in order to reduce the morbidity of PSA screening and early detection of prostate cancer, more needs to be done,” writes Badar M. Mian, MD.

Results of a study analyzing global trends in mortality attributable to urolithiasis show that the rate declined over a recent 20-year period.

Researchers have found that the anxiety men often experience after being diagnosed with prostate cancer could lead to potentially unnecessary treatment options.

Researchers evaluate an experimental treatment called vascular-targeted photodynamic therapy in men with localized prostate cancer.

Getting your finances in order can be overwhelming; here are a few good places to start. Plus, find out if it’s too late to make an IRA contribution.

Results of a 2-year clinical trial support switching to a less frequent administration schedule when using zoledronic acid (Zometa) to prevent skeletal-related events in men with prostate cancer.

Findings from two new studies provide insight on the impact of changing recommendations for prostate cancer screening and management.

In the wake of heated criticism about lengthy wait times for veterans’ care at Veterans Health Administration hospitals, the U.S. Department of Veterans Affairs has moved to allow advanced-practice registered nurses to practice to their full authority without physician oversight and regardless of individual state law in VA facilities.

Other pipeline developments discussed include an implantable device for OAB treatment, a subcutaneous hypogonadism treatment, efficacy results for an HPV drug, and the status of a device-based BPH treatment.

In this month's Letters to the Editor, one reader responds to an article on testosterone therapy in women and another looks to address urology's work force shortage.

In this edition of Men’s Health Mythbuster, Matthew Pollard, MD, Jesse N. Mills, MD look at what impact stress really has on the cardiovascular system.

Whether or not medical expulsive therapy (MET) is a sound recommendation for patients with kidney or ureteral stones is a matter of debate.

Our #LetsTalkMensHealth section offers clinical tips on the care of male patients. In 2016, articles in this section tackled a variety of subjects, including the Affordable Care Act, epigenetics and genetics, and BPH and prostate cancer prevention.

Dr. Henry Rosevear apologizes to those he may have hurt with his prescription habits for pain control and discusses the steps he is taking to help remedy the narcotics epidemic.

Administering sipuleucel-T (Provenge) before rather than after androgen deprivation therapy in men with biochemically recurrent prostate cancer appears to result in a more robust immunologic response, according to a recent study.

Statement authors recommend using immunotherapy prior to an androgen receptor-targeted agent in men with metastatic castration-resistant prostate cancer.

Urology resident, Nirmish Singla, MD, goes over some of the ways urologists can stay educated and informed in the infinite and dynamic curriculum that defines the medical field.